115 related articles for article (PubMed ID: 37731313)
21. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.
Zhou L; An J; Hou C; Ding Z; Qiu H; Tang X; Sun A; Chen S; Xu Y; Liu T; Wu D
Hematology; 2021 Dec; 26(1):340-347. PubMed ID: 33840380
[No Abstract] [Full Text] [Related]
23. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Döhner K; Thiede C; Jahn N; Panina E; Gambietz A; Larson RA; Prior TW; Marcucci G; Jones D; Krauter J; Heuser M; Voso MT; Ottone T; Nomdedeu JF; Mandrekar SJ; Klisovic RB; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte T; Jansen JH; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Gathmann I; Benner A; Pallaud C; Stone RM; Döhner H; Bloomfield CD
Blood; 2020 Jan; 135(5):371-380. PubMed ID: 31826241
[TBL] [Abstract][Full Text] [Related]
24. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Hansen DK; Kim J; Thompson Z; Hussaini M; Nishihori T; Ahmad A; Elmariah H; Faramand R; Mishra A; Davila ML; Khimani F; Lazaryan A; Sallman D; Liu H; Perez LE; Fernandez H; Nieder ML; Lancet JE; Pidala JA; Anasetti C; Bejanyan N
Transplant Cell Ther; 2021 Mar; 27(3):256.e1-256.e7. PubMed ID: 33781526
[TBL] [Abstract][Full Text] [Related]
25. High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia.
Senjo H; Onozawa M; Hidaka D; Yokoyama S; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Hashimoto D; Kondo T; Teshima T
Sci Rep; 2022 May; 12(1):8885. PubMed ID: 35614177
[TBL] [Abstract][Full Text] [Related]
26. ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.
Keren-Froim N; Heering G; Sharvit G; Zlotnik M; Nagler A; Shimoni A; Avigdor A; Canaani J
Ann Hematol; 2022 Feb; 101(2):309-316. PubMed ID: 34989829
[TBL] [Abstract][Full Text] [Related]
27. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
[TBL] [Abstract][Full Text] [Related]
28. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
Eisfeld AK; Kohlschmidt J; Mims A; Nicolet D; Walker CJ; Blachly JS; Carroll AJ; Papaioannou D; Kolitz JE; Powell BE; Stone RM; de la Chapelle A; Byrd JC; Mrózek K; Bloomfield CD
Leukemia; 2020 Dec; 34(12):3215-3227. PubMed ID: 32461631
[TBL] [Abstract][Full Text] [Related]
29. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.
Benicio MTL; Ribeiro AFT; Américo AD; Furtado FM; Glória AB; Lima AS; Santos SM; Xavier SG; Lucena-Araujo AR; Fagundes EM; Rego EM
Leuk Res; 2017 Sep; 60():109-114. PubMed ID: 28777950
[TBL] [Abstract][Full Text] [Related]
31. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
32. Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.
Song GY; Kim HJ; Kim T; Ahn SY; Jung SH; Kim M; Yang DH; Lee JJ; Kim MY; Cheong JW; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Park SK; Kim SH; Choi CK; Kim HJ; Ahn JS; Kim DDH
Sci Rep; 2024 Apr; 14(1):8517. PubMed ID: 38609396
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
[No Abstract] [Full Text] [Related]
34. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
Mi Y; Xue Y; Yu W; Liu S; Zhao Y; Meng Q; Bian S; Wang J
Leuk Lymphoma; 2008 Mar; 49(3):524-30. PubMed ID: 18297530
[TBL] [Abstract][Full Text] [Related]
36. Low Platelet Counts at Diagnosis Predict Better Survival for Patients with Intermediate-Risk Acute Myeloid Leukemia.
Zhang Y; Gu H; Chen Q; Zhang Y; Cheng H; Yang J; Wang J; Hu X
Acta Haematol; 2020; 143(1):9-18. PubMed ID: 31167182
[TBL] [Abstract][Full Text] [Related]
37. Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation.
Hemmati PG; Vuong LG; Terwey TH; Jehn CF; le Coutre P; Penack O; Na IK; Dörken B; Arnold R
Eur J Haematol; 2017 Feb; 98(2):160-168. PubMed ID: 27706846
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia.
Schneider T; Flörcken A; Singh A; Türkmen S; Burmeister T; Anagnostopoulos I; Pezzutto A; Dörken B; Westermann J
Ann Hematol; 2015 Aug; 94(8):1337-45. PubMed ID: 25994787
[TBL] [Abstract][Full Text] [Related]
40. Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia.
Berger MD; Heini AD; Seipel K; Mueller B; Angelillo-Scherrer A; Pabst T
Hematol Oncol; 2017 Dec; 35(4):789-796. PubMed ID: 27301773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
